Revenue: As of FY2025 Q3, the actual value is USD 0.EPS: As of FY2025 Q3, the actual value is USD -2.21.EBIT: As of FY2025 Q3, the actual value is USD -5.007 M.<h3>Operational Metrics</h3><ul><li>Net Loss: The net loss for the three months ended September 30, 2025, was $5.2 million, compared to $5.1 million for the same period in 2024, representing a 2% increase.</li><li>Research and Development Expenses: R&amp;D expenses increased by 10% to $2.4 million for the three months ended September 30, 2025, from $2.2 million in the same period in 2024.</li><li>General and Administrative Expenses: G&amp;A expenses decreased by 13% to $2.7 million for the three months ended September 30, 2025, from $3.1 million in the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was $16.2 million, compared to $14.3 million for the same period in 2024.</li><li>Net Cash Used in Investing Activities: Net cash used in investing activities was $0.1 million for the nine months ended September 30, 2025, compared to $11,000 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: Net cash provided by financing activities was $17.1 million for the nine months ended September 30, 2025, compared to $14.3 million for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Warrants: As of September 30, 2025, the company had outstanding warrants to purchase 5,026,613 shares of Common Stock.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to file an IND for a Phase I trial by the end of 2026 with CLD-401, the first compound from the RedTail platform, delivering IL-15 superagonist to the tumor microenvironment.</li><li>Non-Core Business: The company sold its ownership interest in Nova Cell on October 27, 2025, and Nova Cell ceased to be a subsidiary of the company.</li></ul><h3>Priority</h3><ul><li>The company emphasizes the development of its RedTail platform, which represents a major advancement in the space of oncolytic virus in oncology.</li></ul>

Global X S&P 500 U.S. Mkt Ldr TOP 50 ETF | 10-Q: FY2025 Q3 Revenue: USD 0